3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Gynecologic
2
Breast
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
4
pembrolizumab
3
Docetaxel
3
Cryosurgery
3
Biopsy
3
eribulin
2
durvalumab
2
balstilimab
2
atezolizumab
2
aflibercept
2
Zoledronic Acid
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Irinotecan
2
Gene Expression Profiling
2
Fulvestrant
2
Cisplatin
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled